NEW cancer drugs are being made available for patients on Wearside.
Five new treatments have been given the green light after recent meetings of the North of England Cancer Drug Approvals Group.
The drugs will help patients who are suffering from skin, bone, blood, breast and ovarian cancers.
Of the drugs, Rituximab, which treats cancer of the blood, is being funded through primary care trust budgets with the others – Vemurafenib, Denosumab, Eribulin and Bevacizumab (Avastin) – being paid for by the cancer drug fund allocation from the Government.
The decision follows an announcement last year that the North East would receive £11.3million to spend on cancer drugs not funded by the NHS during 2011/12.